{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Homozygous+Familial+Hypercholesterolemia&page=2",
    "query": {
      "condition": "Homozygous Familial Hypercholesterolemia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Homozygous+Familial+Hypercholesterolemia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T12:30:22.024Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05217667",
      "title": "Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "ARO-ANG 3 Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arrowhead Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2022-04-22",
      "completion_date": "2025-11-13",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 2,
      "location_summary": "Mount Sinai, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Mount Sinai",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05217667"
    },
    {
      "nct_id": "NCT03135184",
      "title": "HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia",
        "HoFH"
      ],
      "interventions": [
        {
          "name": "HDL Therapeutics PDS-2 System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "HDL Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2018-01-26",
      "completion_date": "2019-08",
      "has_results": false,
      "last_update_posted_date": "2019-05-23",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03135184"
    },
    {
      "nct_id": "NCT01109368",
      "title": "The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "The Rogosin Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "2010-06",
      "completion_date": "2030-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01109368"
    },
    {
      "nct_id": "NCT02651675",
      "title": "A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia (HoFH)"
      ],
      "interventions": [
        {
          "name": "AAV directed hLDLR gene therapy",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "REGENXBIO Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-03",
      "completion_date": "2020-11-27",
      "has_results": true,
      "last_update_posted_date": "2023-07-13",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 5,
      "location_summary": "Boca Raton, Florida • Kansas City, Kansas • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02651675"
    },
    {
      "nct_id": "NCT03409744",
      "title": "Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "evinacumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2018-03-13",
      "completion_date": "2023-04-13",
      "has_results": true,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Boca Raton, Florida • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03409744"
    },
    {
      "nct_id": "NCT00280995",
      "title": "Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia, Familial"
      ],
      "interventions": [
        {
          "name": "ISIS 301012",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kastle Therapeutics, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2006-01",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2016-08-03",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • New York, New York • Winston-Salem, North Carolina + 2 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00280995"
    },
    {
      "nct_id": "NCT07037771",
      "title": "A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "zodasiran Injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arrowhead Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-06-17",
      "completion_date": "2027-08-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 4,
      "location_summary": "Park Ridge, Illinois • New York, New York • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07037771"
    },
    {
      "nct_id": "NCT03814187",
      "title": "Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ASCVD",
        "Elevated Cholesterol",
        "Heterozygous Familial Hypercholesterolemia",
        "Homozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Inclisiran Sodium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3275,
      "start_date": "2019-04-16",
      "completion_date": "2023-02-13",
      "has_results": true,
      "last_update_posted_date": "2024-03-06",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 141,
      "location_summary": "Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 109 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Foley",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814187"
    },
    {
      "nct_id": "NCT02265952",
      "title": "Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "REGN1500 250 mg SC/15 mg/kg IV/450 mg SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2015-02-04",
      "completion_date": "2018-07-23",
      "has_results": true,
      "last_update_posted_date": "2019-12-09",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Philadelphia, Pennsylvania • Dallas, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02265952"
    },
    {
      "nct_id": "NCT04815005",
      "title": "HoFH, the International Clinical Collaborators Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2017-01-24",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-06-11T12:30:22.024Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04815005"
    }
  ]
}